160 related articles for article (PubMed ID: 16080558)
1. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
Shimizu T; Yamada Y; Yasui H; Shirao K; Fukuoka M
Anticancer Res; 2005; 25(4):2997-3001. PubMed ID: 16080558
[TBL] [Abstract][Full Text] [Related]
2. [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].
Morimoto S; Shono Y; Tsuji T; Makihara K; Kawato N; Hachino Y; Mishima H; Tsujinaka T; Tabuse K
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2083-9. PubMed ID: 14712769
[TBL] [Abstract][Full Text] [Related]
3. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Yamagata S; Nakata B; Hirakawa K
Oncol Rep; 2004 Nov; 12(5):973-8. PubMed ID: 15492780
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.
Miyamoto S; Boku N; Ohtsu A; Yoshida S; Ochiai A; Okabe H; Fukushima M
Int J Oncol; 2000 Oct; 17(4):653-8. PubMed ID: 10995874
[TBL] [Abstract][Full Text] [Related]
5. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
6. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
Kuramochi H; Hayashi K; Uchida K; Nakajima G; Hatori T; Danenberg KD; Danenberg PV; Yamamoto M
Cancer Chemother Pharmacol; 2008 Dec; 63(1):85-9. PubMed ID: 18309485
[TBL] [Abstract][Full Text] [Related]
7. [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
Sakurai Y; Kamoshida S; Furuta S; Sunagawa R; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1147-55. PubMed ID: 18633253
[TBL] [Abstract][Full Text] [Related]
8. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
9. Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma.
Hisamitsu K; Tsujitani S; Yamaguchi K; Fukuda K; Konishi I; Kaibara N
Anticancer Res; 2004; 24(4):2495-501. PubMed ID: 15330204
[TBL] [Abstract][Full Text] [Related]
10. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
11. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
Yamada Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
[TBL] [Abstract][Full Text] [Related]
12. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Tokunaga Y; Sasaki H; Saito T
Surgery; 2007 Mar; 141(3):346-53. PubMed ID: 17349846
[TBL] [Abstract][Full Text] [Related]
13. Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Tokunaga Y; Takahashi K; Saito T
Hepatogastroenterology; 2005; 52(66):1715-21. PubMed ID: 16334763
[TBL] [Abstract][Full Text] [Related]
14. Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma.
Nozawa H; Tsukui H; Nishida K; Yakumaru K; Nagawa H; Sekikawa T
Cancer Chemother Pharmacol; 2002 Apr; 49(4):267-73. PubMed ID: 11914904
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Usuki H; Ishimura K; Yachida S; Hagiike M; Okano K; Izuishi K; Karasawa Y; Goda F; Maeta H
Gastric Cancer; 2003; 6 Suppl 1():66-70. PubMed ID: 12775023
[TBL] [Abstract][Full Text] [Related]
16. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
Fukuda H; Takiguchi N; Koda K; Oda K; Seike K; Miyazaki M
Cancer Invest; 2006; 24(3):235-41. PubMed ID: 16809149
[TBL] [Abstract][Full Text] [Related]
17. The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer.
Li Y; Mizutani Y; Shiraishi T; Nakamura T; Mikami K; Takaha N; Okihara K; Kawauchi A; Sakai T; Miki T
BJU Int; 2007 Mar; 99(3):663-8. PubMed ID: 17092280
[TBL] [Abstract][Full Text] [Related]
18. [Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients].
Uyama R; Yoshizawa Y; Tajiri T; Endo Y; Mitsuya T; Sanada Y
Gan To Kagaku Ryoho; 2006 May; 33(5):625-9. PubMed ID: 16685161
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
Nakagawa T; Tanaka F; Takata T; Matsuoka K; Miyahara R; Otake Y; Yanagihara K; Fukushimab M; Wada H
J Surg Oncol; 2002 Oct; 81(2):87-92. PubMed ID: 12355409
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]